Everyone would like to see integration of genomic, metabolomic, epigenomic, proteomic, transcriptomic, etc. data analyzed in the context of clinical disease, environmental influences, and even end-organ effects (lung versus heart or blood as an example). Rarely can this occur on small cohorts, but rarely are funds available to take maximum use of existing large cohorts and the samples and information collected within them. Multi-million dollar cohorts with multi-million dollar sample storage requirements deserve multi-million dollar investment in sample analysis and data integration (what good is a sample stored in a freezer). How can we fund these efforts and generate a mechanism whereby samples are not left unanalyzed.
Voting on Ideas
Vote for your favorite ideas by clicking on the up arrow.To undo an upvote, simply click the arrow again. This second click removes your vote.